Amgen Inc.
Methods of treating non-alcoholic steatohepatitis using FGF21 mutants
Last updated:
Abstract:
The invention provides methods for treating non-alcoholic steatohepatitis (NASH) using FGF21 mutant polypeptides.
Status:
Grant
Type:
Utility
Filling date:
1 Jun 2018
Issue date:
27 Jul 2021